Marco Giorgio received the B.Sc. degree in Biology upon working on transgenic model of HBV at the University of Rome. He did the post-graduate training at the IRBM in Pomezia, studying the biochemistry of IL-6. Awarded by a fellowship from AIRC, he investigated gene function in transgenic mice and generated cancer models at the Regina Elena cancer institute. Then, for two years at the MSKCC in New York, he started working on the genetic link between cancer and aging. He received the PhD degree in Biotechnology discussing a thesis on the p66Shc aging gene and joined the IEO in Milan, where, in the Department of Experimental Oncology, he continued investigating the mechanisms of aging involved in tumorigenesis and currently he collaborate to investigate the metabolic adaptation of metastasis.

Since 2018 he is associated professor of Biochemistry at the Department of Biomedical Science of the University of Padova where he studies the molecular mechanisms of aging.

What happen, at molecular level, within the mammalian cell, during aging? The working hypothesis is that biochemical "errors" that occur over time, at first remodel cellular phenotype trough processes of plasticity and selective adaptation, then accumulate and determine typical aging dysfunctions. At experimental level, the Marco Giorgio focuses on the interactions between bioenergetics, redox balance and DNA metabolism. In this field he contributed with the characterization of the p66Shc "aging gene" and the role of mitochondrial redox signalling in the onset of aging associated diseases.

The studies of Prof. Marco Giorgio are reported in 90 publications, of which 75 are original articles in international peer reviewed journals in the fields of biochemistry, molecular biology, genetics and medicine, 11 "reviews" and 5 book chapters, cited 8000 times for an H index of 37 according to "Scopus - Orcid - Web of Science" (

Last 3 years research articles

1.    Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. Costantino S, Paneni F, Virdis A, Hussain S, Mohammed SA, Capretti G, Akhmedov A, Dalgaard K, Chiandotto S, Pospisilik JA, Jenuwein T, Giorgio M, Volpe M, Taddei S, Lüscher TF, Cosentino F. Eur Heart J. 2019. 40:383-91.

2.    Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway. Albiero M, Ciciliot S, Tedesco S, Menegazzo L, D'Anna M, Scattolini V, Cappellari R, Zuccolotto G, Rosato A, Cignarella A, Giorgio M, Avogaro A, Fadini GP. Diabetes. 2019. 68:1303-14.

3.    Epigenomic profiling of archived FFPE tissues by enhanced PAT-ChIP (EPAT-ChIP) technology. Amatori S, Persico G, Paolicelli C, Hillje R, Sahnane N, Corini F, Furlan D, Luzi L, Minucci S, Giorgio M, Pelicci PG, Fanelli M. Clin Epigenetics. 2018. 10:143.

4.    Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma. Ravà M, Aleco D’Andrea A, Nicoli P, Gritti I, Donati G, Doni M, Giorgio M, Olivero D, Amati B. Sci Transl Med. 2018. 10:426.

5.    Glucose and Lactate Miniaturized Biosensors for SECM-Based High-Spatial Resolution Analysis: A Comparative Study. Soldà A, Valenti G, Marcaccio M, Giorgio M, Pelicci PG, Paolucci F, Rapino S. ACS Sensors. 2017. 2:1310-18

6.    Dietary cyanidin 3-glucoside from purple corn ameliorates doxorubicin-induced cardiotoxicity in mice. Petroni K, Trinei M, Fornari M, Calvenzani V, Marinelli A, Micheli LA, Pilu R, Matros A, Mock HP, Tonelli C, Giorgio M. Nutrition Metabolism and Cardiovascular Diseases. 2017. 27.462-69.

7.    Diagnostic and Prognostic Utility of Circulating Cytochrome c in Acute Myocardial Infarction. Marenzi G, Cosentino N, Boeddinghaus J, Trinei M, Giorgio M, Milazzo V, Moltrasio M, Cardinale D, Sandri MT, Veglia F, Bonomi A, Kaech M, Twerenbold R, Nestelberger T, Reichlin T, Wildi K, Shrestha S, Kozhuharov N, Sabti Z, Cipolla CM, Mueller C, Bartorelli AL. Circ Res. 2016. 119:1339-46.

8.    Novel Insights into the PKCβ-dependent Regulation of the Oxidoreductase p66Shc. Haller M, Khalid S, Kremser L, Fresser F, Furlan T, Hermann M, Guenther J, Drasche A, Leitges M, Giorgio M, Baier G, Lindner H, Troppmair J. J Biol Chem. 2016. 291:23557-68.

9.    The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas. D’Andrea A, Gritti I, Nicoli P, Giorgio M, Doni M, Conti A, Bianchi V, Casoli L, Sabò A, Mironov A, Beznoussenko GV, Amati B. Oncotarget. 2016. 7:72415-30.

10.Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis. Bigi A,  Beltrami E, Trinei M, Stendardo M, Pelicci PG, Giorgio M. Oncogene.  2016. 35:5132-43.

11. P66SHC deletion improves fertility and progeric phenotype of late-generation TERC-deficient mice but not their short lifespan. Giorgio M, Stendardo M, Migliaccio E, Pelicci PG. Aging Cell. 2016. 15:446-54.

12.Cyanidin-3-O-β-glucoside and protocatechuic acid activate AMPK/mTOR/S6K pathway and improve glucose homeostasis in mice. Talagavadi V, Rapisarda P, Galvano F, Pelicci PG, Giorgio M. Journal of Functional Foods. 2016. 21:338-48.


  • University of Padova
  • Ministry of Health  -  Grant RF
  • European Institute of Oncology, Milan

Educational offer